[{"id":"b2ad8db4-6b5f-4044-a437-6f3a40d4d944","acronym":"IOV-GM1-201","url":"https://clinicaltrials.gov/study/NCT05361174","created_at":"2022-05-05T00:56:35.266Z","updated_at":"2024-07-02T16:35:39.294Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer","source_id_and_acronym":"NCT05361174 - IOV-GM1-201","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • IOV-4001"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2023-08-22"}]